Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Horizon Therapeutics Public Limited Company shares valued at $65,044 were sold by Pasternak Andy on Jun 10. At $85.36 per share, Pasternak Andy sold 762 shares. The insider’s holdings dropped to 38,897 shares worth approximately $3.23 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Also, Walbert Timothy P sold 25,000 shares, netting a total of over 2,308,468 in proceeds. Following the sale of shares at $92.34 each, the insider now holds 435,826 shares.
Before that, Walbert Timothy P had sold 25,000 shares from its account. In a trade valued at $2,311,980, the Chairman, President and CEO traded Horizon Therapeutics Public Limited Company shares for $92.48 each. Upon closing the transaction, the insider’s holdings decreased to 25,000 shares, worth approximately $36.12 million.
As published in their initiating research note from UBS on June 14, 2022, Horizon Therapeutics Public Limited Company [HZNP] has been a Buy and the price target has been revised to $139. This represents a 40.33% premium over Wednesday’s closing price. As of May 23, 2022, SVB Leerink has initiated its “Mkt perform” rating for HZNP. Earlier on March 15, 2022, Oppenheimer initiated its rating. Their recommendation was “an Outperform” for HZNP stock.
Analyzing HZNP’s Price Performance
On Wednesday, Horizon Therapeutics Public Limited Company [NASDAQ: HZNP] rose 0.16% to $82.94. The stock’s lowest price that day was $82.01, but it reached a high of $83.78 in the same session. During the last five days, there has been a surge of approximately 2.05%. Over the course of the year, Horizon Therapeutics Public Limited Company shares have dropped approximately -23.03%. Shares of the company reached a 52-week high of $117.49 on 04/21/22 and a 52-week low of $78.85 on 06/16/22. A 50-day SMA is recorded $94.35, while a 200-day SMA reached $101.75. Nevertheless, trading volume fell to 1.45 million shares from 1.63 million shares the previous day.
Support And Resistance Levels for Horizon Therapeutics Public Limited Company (HZNP)
According to the 24-hour chart, there is a support level at 82.04, which, if violated, would cause prices to drop to 81.14. In the upper region, resistance lies at 83.81. The next price resistance is at 84.68. RSI (Relative Strength Index) is 41.10 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -2.86, which suggests the price will decrease in the coming days. Percent R is at 71.58%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Horizon Therapeutics Public Limited Company (HZNP)?
According to The Vanguard Group, Inc. filings, the company currently owns 19,892,801 shares, which is about 8.68% of the total HZNP shares outstanding. The investor’s shares have appreciated by 212,145 from its previous 13-F filing of 19680656.0 shares. With the completion of the sale, Fidelity Management & Research Co’s stake is now worth $1,311,030,660. BlackRock Fund Advisors acquire a 1.13% interest valued at $817.47 million while Capital Research & Management Co 7,075,657 stake. A total of 18,490 shares of Horizon Therapeutics Public Limited Company by Janus Henderson Investors US LLC during the quarter, and -2,795,000 were sold by Avoro Capital Advisor LLC. In its current portfolio, Paulson & Co., Inc. holds 5,614,000 shares valued at $503.52 million.
In terms of Horizon Therapeutics Public Limited Company share price expectations, FactSet research, analysts set an average price target of $138.64 in the next 12 months, up nearly 69.06% from the previous closing price of $82.81. Analysts anticipate Horizon Therapeutics Public Limited Company stock to reach $162.00 by 2022, with the lowest price target being $95.00. In spite of this, 14 analysts ranked Horizon Therapeutics Public Limited Company stock as a Buy at the end of 2022. On December 08, 2021, Wells Fargo assigned a price target of “an Overweight” to the stock and initiated coverage with a $137.